Mardi Dier Sells 1,982 Shares of Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) CFO Mardi Dier sold 1,982 shares of the business’s stock in a transaction dated Friday, March 6th. The stock was sold at an average price of $430.87, for a total transaction of $853,984.34. Following the transaction, the chief financial officer owned 12,490 shares in the company, valued at $5,381,566.30. The trade was a 13.70% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.

Mardi Dier also recently made the following trade(s):

• On Monday, March 2nd, Mardi Dier sold 1,183 shares of Madrigal Pharmaceuticals stock. The shares were sold at an average price of $427.21, for a total transaction of $505,389.43.

Madrigal Pharmaceuticals Stock Down 1.5%

MDGL stock opened at $432.83 on Friday. The company has a current ratio of 4.01, a quick ratio of 3.77 and a debt-to-equity ratio of 0.56. The firm has a 50-day moving average of $492.64 and a two-hundred day moving average of $487.47. Madrigal Pharmaceuticals, Inc. has a 12 month low of $265.00 and a 12 month high of $615.00. The company has a market cap of $9.93 billion, a price-to-earnings ratio of -33.63 and a beta of -0.97.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last issued its earnings results on Thursday, February 19th. The biopharmaceutical company reported ($2.57) earnings per share for the quarter, missing the consensus estimate of $0.04 by ($2.61). The company had revenue of $321.08 million for the quarter, compared to analyst estimates of $310.36 million. Madrigal Pharmaceuticals had a negative return on equity of 43.76% and a negative net margin of 30.08%.The company’s revenue for the quarter was up 210.8% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.71) earnings per share. As a group, analysts forecast that Madrigal Pharmaceuticals, Inc. will post -23.47 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Madrigal Pharmaceuticals

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. AlphaQuest LLC lifted its stake in shares of Madrigal Pharmaceuticals by 412.5% in the 2nd quarter. AlphaQuest LLC now owns 82 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 66 shares during the last quarter. Flagship Harbor Advisors LLC acquired a new stake in shares of Madrigal Pharmaceuticals during the 4th quarter worth about $29,000. Mather Group LLC. acquired a new stake in shares of Madrigal Pharmaceuticals during the 3rd quarter worth about $33,000. Global Retirement Partners LLC raised its holdings in Madrigal Pharmaceuticals by 221.7% in the 3rd quarter. Global Retirement Partners LLC now owns 74 shares of the biopharmaceutical company’s stock valued at $34,000 after buying an additional 51 shares during the period. Finally, First Horizon Corp purchased a new stake in Madrigal Pharmaceuticals in the 3rd quarter valued at about $34,000. Institutional investors and hedge funds own 98.50% of the company’s stock.

Madrigal Pharmaceuticals News Roundup

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Company granted inducement equity awards to 20 new non‑executive hires under Nasdaq Rule 5635(c)(4), which can help recruit talent and support execution of the pipeline programs. Madrigal Announces Grants of Inducement Awards
• Neutral Sentiment: All insider trades were formally reported via SEC Form 4 filings (standard disclosure), so the transactions are public and fully documented. Example SEC Form 4 Filing
• Negative Sentiment: CEO William John Sibold sold 1,663 shares (~$718k); his holdings fell ~1.02% after the sale. CEO Form 4
• Negative Sentiment: CFO Mardi Dier sold 1,982 shares (~$854k); this represented a ~13.7% reduction in her ownership. Large percentage cuts by the CFO can be read as a stronger negative signal. CFO Form 4
• Negative Sentiment: General Counsel Shannon T. Kelley sold 360 shares (~$155k), a ~2.88% position reduction. GC Form 4
• Negative Sentiment: Director Rebecca Taub sold 491 shares (~$212k); she still retains a large stake (~452k shares) but reduced ownership slightly. Director Form 4
• Negative Sentiment: Insider Carole Huntsman sold 419 shares (~$181k), a ~3.20% decrease in her holding. Insider Form 4

Wall Street Analyst Weigh In

Several brokerages have issued reports on MDGL. UBS Group set a $900.00 target price on Madrigal Pharmaceuticals in a report on Friday, December 19th. Citizens Jmp lifted their price target on Madrigal Pharmaceuticals from $527.00 to $745.00 and gave the stock a “market outperform” rating in a report on Tuesday, January 20th. Weiss Ratings reissued a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, January 22nd. Bank of America dropped their price objective on shares of Madrigal Pharmaceuticals from $570.00 to $529.00 and set a “neutral” rating for the company in a report on Friday, February 20th. Finally, Truist Financial raised their price objective on shares of Madrigal Pharmaceuticals from $580.00 to $640.00 and gave the stock a “buy” rating in a research report on Wednesday, November 19th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $685.31.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on the development of innovative therapies for cardiovascular, metabolic and liver diseases. The company’s pipeline centers on novel, liver-directed agents designed to address significant unmet medical needs, with an emphasis on nonalcoholic steatohepatitis (NASH) and related metabolic disorders.

The lead product candidate, resmetirom (MGL-3196), is an orally administered, selective thyroid hormone receptor-β agonist in Phase 3 development for the treatment of NASH.